Psilocybin prevented chemotherapy-induced peripheral neuropathy in several preclinical models, according to research published in Science on September 3, 2026.
The result is an early laboratory finding, not evidence that patients should use psilocybin during cancer treatment. Researchers are preparing clinical evaluation, and safety and effectiveness in humans remain unproven.
How psilocybin chemotherapy neuropathy was studied
Researchers at the University of Texas MD Anderson Cancer Center tested whether psilocybin could protect nerves from damage associated with chemotherapy. In mouse models, two doses given before treatment preserved sensory nerves and reduced abnormal sensitivity across repeated chemotherapy cycles.
The experiments included cisplatin, a platinum-based medicine that can cause numbness, pain, burning and loss of sensation. Chemotherapy-induced peripheral neuropathy can persist and may force clinicians to reduce or change otherwise effective treatment.
A possible biological pathway
The researchers linked protection to the serotonin 5-HT2A receptor and to preservation of mitochondrial trafficking within nerve cells. Mitochondria supply cellular energy, and their movement along nerves is important for function and repair.
A non-hallucinogenic compound acting on a related pathway also produced protective effects in the models. That observation may help researchers separate potential nerve protection from psilocybin’s psychoactive effects.
Cancer treatment was not weakened in the models
MD Anderson reported that the intervention did not reduce chemotherapy’s anti-tumour activity in the tested models. This is an essential question for any supportive treatment, because symptom prevention cannot come at the cost of cancer control.
However, animal models cannot reproduce every aspect of human disease. Different chemotherapy medicines also damage nerves through different mechanisms, so results with one regimen may not apply broadly.
What the study does not prove
The research does not establish an appropriate human dose, timing, interaction profile or long-term safety. Psilocybin can have psychological and cardiovascular effects and is regulated differently across jurisdictions.
Patients should not self-medicate or combine psychoactive substances with cancer drugs. Treatment decisions belong with an oncology team familiar with the patient’s medicines and health conditions.
Next research steps
A clinical trial will need to determine whether the nerve-protective signal translates to people, whether benefits outweigh risks and whether a non-hallucinogenic alternative is feasible.
The study is significant because it identifies a testable mechanism and a potential prevention strategy. Its promise should be described accurately: strong enough for further research, but not yet a clinical recommendation.
